why choose us

First received: November 28, 2022

Clinical Trial: Tocilizumab for Acute Chest Syndrome

Study Status: Completed

Recruit Status: RECRUITING

Condition: Sickle Cell Disease

Study Type: INTERVENTIONAL


Official Title: Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease

Brief Summary: The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease.Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19.Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigators are hopeful that…

Read more